2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
June 14th 2022
Apalutamide plus androgen deprivation therapy and radiotherapy was evaluated in patients with high- and very high–risk localized or locally advanced prostate cancer, with RT schedules that are reflective of recommended practice guidelines.
June 6th 2022
Mobocertinib may have limited intracranial activity in patients with EGFR exon 20 insertion–positive, non–small cell lung cancer with brain metastases at baseline, given the numerically lower response rate observed with the agent in this population.
June 3rd 2022
Ibrutinib in combination with bendamustine and rituximab with rituximab maintenance elicited a significant improvement in progression-free survival compared with standard chemoimmunotherapy in older patients with mantle cell lymphoma.
May 26th 2022
Black patients were less likely to be included in clinical trials that investigate newer treatments for metastatic breast cancer, despite having the highest death rate and shortest survival outcomes when compared with other racial and ethnic groups in the United States.
March 11th 2022
Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research.
February 19th 2022
Updated data support the common use of cabozantinib in this setting without new safety signals in patients with metastatic renal cell carcinoma.
January 21st 2022
Transarterial chemoembolization combined with lenvatinib plus sintilimab was safe and effective for patients with unresectable hepatocellular carcinoma.
December 13th 2021
The results also demonstrated no significant difference in overall survival benefit between the treatment groups. However, almost all patients switched from FCR to ibrutinib or another regimen after disease relapse.
December 11th 2021
The use of ibrutinib plus venetoclax in the first-line setting for patients with previously untreated chronic lymphocytic leukemia continues to provide deep, durable responses, according to updated results from the MRD cohort of the phase 2 CAPTIVATE trial.
September 19th 2021
Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.
September 13th 2021
Improvements in quality of life, antitumor immune responses, and inflammation could be resulting benefits of the incorporation of regular yoga practice in the lives of men with prostate cancer who are undergoing prostatectomy.
September 13th 2021
Smoking status is not often reported on genitourinary cancer clinical trials, which limits understanding of how smoking impacts the treatment, survival, and quality of life of this patient population.
June 12th 2021
Compared to currently available therapies, treatment with axicabtagene ciloleucel induced substantial objective response rate, progression-free survival, time to next treatment and overall survival improvements in patients with relapsed/refractory follicular lymphoma.
June 5th 2021
Treatment with selpercatinib demonstrated consistent efficacy in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments.
June 5th 2021
Treatment with aumolertinib was associated with prolonged survival and duration of response in patients with non–small cell lung cancer.
June 4th 2021
Updated findings from the ARROW trial demonstrated that pralsetinib could benefit those with RET fusion–positive non–small cell lung cancer and is a well-tolerated agent in the patient population.
February 12th 2021
February 12, 2021 - Patients with advanced renal cell carcinoma reported improved health-related quality of life when treated with nivolumab plus cabozantinib compared with sunitinib
January 28th 2021
January 28, 2021 - Immuno-oncology therapies provided significant potential health gains for both patients and the population, although age should be taken into account to improve accuracy and avoid bias.
January 15th 2021
January 15, 2021 - Patients with esophageal/gastroesophageal cancer treated with nivolumab had improved esophageal-specific and general quality of life, although trends were similar in those treated with placebo.
December 10th 2020
December 10, 2020 - Women who survive breast cancer may have more difficulty in becoming pregnant when compared to the general population, and have a risk of preterm labor, but most deliver healthy babies and experience no detrimental effects on their long-term survival.